Twitxy Saved

Precision BioSciences

Verified account This account is verified. Learn more

@PrecisionBioSci

Pioneers in genome editing using our proprietary ARCUS® technology to develop potentially curative therapeutics to overcome cancer and cure genetic disease.
Durham, NC precisionbiosciences.com Joined January 2018
325 Following 1.6K Followers 481 Posts

Latest posts 5

Precision BioSciences Verified account @PrecisionBioSci
From the HBV Cure Workshop to AASLD The Liver Meeting 2026, PBGENE-HBV took the stage in Denver!

At AASLD The Liver Meeting® 2026, ELIMINATE-B lead investigator Man Fung Yuen, MD, PhD, Chair Professor of The University of Hong Kong and Chief of the Division of Gastroenterology and Hepatology, Queen Mary Hospital, delivered a late-breaking oral presentation featuring new and updated data from 25 patients across 59 administrations in the Phase 1 ELIMINATE-B trial.

At the expected go-forward dose of 0.4 mg/kg, PBGENE-HBV achieved pgRNA loss to undetectable in 100% of evaluable patients.

Emily B. Harrison, PhD, Director of Translational Sciences, also presented PBGENE-HBV data at the HBV Cure Workshop in Denver.

PBGENE-HBV is the first and only in vivo gene editing therapy designed to eliminate the root cause of chronic hepatitis B, covalently closed circular DNA (cccDNA), to drive viral cure measured by sustained undetectable HBV DNA.

Read the full release, loom.ly/MZYmQqI

#PrecisionBioSciences #DTIL #HepatitisB #AASLD
Precision BioSciences Verified account @PrecisionBioSci
Precision BioSciences announced the pricing of a $125 million underwritten offering of common stock and pre-funded warrants at a price of $7.75 per share, a premium to the five-day average closing price.

The deal includes participation from new and existing investors, including First Light Asset Management, MPM BioImpact, Bleichroeder LP, Lynx1 Capital Management, Readout Capital, Aberdeen Investments, Driehaus Capital Management, as well as other leading life sciences investors.

Precision intends to use the net proceeds to fund the continued research and development of PBGENE-HBV and PBGENE-DMD, and for working capital and general corporate purposes.

Read the full release, loom.ly/8omd6gA

#PrecisionBioSciences $DTIL
Precision BioSciences Verified account @PrecisionBioSci
Precision BioSciences has been selected to deliver a late-breaking oral presentation on PBGENE‑HBV at AASLD’s The Liver Meeting 2026, taking place November 5–9 in Denver, Colorado.

MF Yuen MD, Ph.D., will present “Durable pgRNA loss in both HBeAg positive and negative patients treated with PBGENE-HBV supports path towards viral cure” on November 8, from 2:15–2:30 p.m. MST.

PBGENE-HBV is our wholly owned in vivo gene editing program being evaluated in the Phase 1 ELIMINATE‑B trial as a potential viral cure for chronic hepatitis B. The program is designed to target and eliminate cccDNA, the source of new infectious HBV particles.

Read the announcement:
loom.ly/1nD3szU

#PrecisionBioSciences #PBGENEHBV #ELIMINATEB #HepatitisB #AASLD #TheLiverMeeting #GeneEditing #ARCUS $DTIL
0:12
Precision BioSciences Verified account @PrecisionBioSci
Precision in Japan!

Dr. Sam Collins represented Precision BioSciences at the World Muscle Society conference last week.

We’re grateful for the opportunity to connect with the neuromuscular community as we advance PBGENE‑DMD, our investigational in vivo gene editing program for Duchenne muscular dystrophy.

Read the latest update, loom.ly/QIQX9EA

#PrecisionBioSciences #WorldMuscleSociety #Duchenne #DMD #PBGENEDMD #GeneEditing